NCT07021976Active, not recruitingPhase 3
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 228 (actual)
- First submitted
- 6 Jun 2025
- Start date
- 11 Aug 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07021976
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 228
- From 11 Aug 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM).
- Had a history of severe valvular heart disease.
- Other circumstances where the researchers consider the subjects unsuitable to participate in this trial, such as physical or mental illnesses or conditions that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.
Lab values
- Abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by the researcher to be unsuitable for inclusion.
Who the study is looking for
- Age 18-85 years old, gender unlimited.
- BMI\<35 kg/m2.
- The diagnosis was obstructive hypertrophic cardiomyopathy.
- Laboratory determination of echocardiography showed that Rest LVOT-G≥50 mmHg, or Rest LVOT-G≥30 mmHg and LVOT-G≥50 mmHg after Valsalva action.
- Echocardiographic laboratory tests showed LVEF≥60%.
- NYHA classification: Grade II - III.
- Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.